Good news! Gluetacs Therapeutics won Top 100 of the Shanghai High-Value Patent Operation Competition and awarded the title of Director Unit of the National Biopharmaceutical Enterprise Platform

ON：2024-12-28 TAGS：GLUETACS THERAPEUTICS

Recently, the 2024 Shanghai High-Value Patent Operation Competition Awards Ceremony was held at the Lippo Sky Tower in Shanghai. After evaluation by the competition’s panel of experts, Gluetacs Therapeutics (Shanghai) Co., Ltd., in collaboration with ShanghaiTech University, was recognized for the outstanding innovation and practical application value with the patent project “Development of the Class 1 innovative drug GT929 and Its Application in the Treatment of Relapsed or Refractory Non-Hodgkin’s Lymphoma.” The project was shortlisted in the top 100 and received a certificate for this achievement, and the project has been granted clinical research approvals from both China and the United States and is conducting Phase I clinical trials, offering the potential for new therapeutic options for patients with advanced non-Hodgkin’s lymphoma. 

Recently, the “Connecting the Yangtze River Delta with Data, Creating a Future of Health” Life Sciences Industry Development Promotion Conference, a concurrent event of the 2024 Shanghai International Biopharma Industry Week, was successfully held in Shanghai. At the conference, Gluetacs Therapeutics was awarded a plaque by the National Biopharma Enterprise Platform, officially becoming a member of the platform’s governing council. This honor not only recognizes the achievements of Gluetacs in the field of biopharma but also affirms the company’s promising future prospects.